The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Discovery and development of SAHA as an anticancer agent
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiological functions of thioredoxin and thioredoxin reductase
Arnér, E. S. J., & Holmgren, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01701.x · Cited by 2,525
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationFriend, C., Scher, W., Holland, J. G., & Sato, T. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.2.378 · Cited by 1,352
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Self-citationKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Self-citationErythroleukemic Differentiation
Marks, P. A., & Rifkind, R. A. (1978) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.47.070178.002223 · Cited by 680
Self-citationKelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Self-citationButler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Self-citationApoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Self-citationGui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Self-citationPeart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Self-citationHistone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Self-citationUngerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Self-citationRapid Alteration of MicroRNA Levels by Histone Deacetylase Inhibition
Scott, G. K., Mattie, M. D., Berger, C. E., Benz, S. C., & Benz, C. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3632 · Cited by 492
Prospects: Histone deacetylase inhibitors
Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 479
Self-citation(2003) · PubMed · Cited by 465
Histone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
The role of the redox protein thioredoxin in cell growth and cancer
Powis, G., Mustacich, D., & Coon, A. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00313-0 · Cited by 443
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420
Self-citationA new group of potent inducers of differentiation in murine erythroleukemia cells.
Reuben, R. C., Wife, R. L., Breslow, R., Rifkind, R. A., & Marks, P. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.3.862 · Cited by 370
Self-citationIdentification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Self-citationGlobal Gene Expression Profiling of Circulating Tumor Cells
Smirnov, D. A., Zweitzig, D. R., Foulk, B. W., Miller, M. C., Doyle, G. V., Pienta, K. J., Meropol, N. J., Weiner, L. M., Cohen, S. J., Moreno, J. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4330 · Cited by 329
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
Li, L.-C., Carroll, P. R., & Dahiya, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji010 · Cited by 299
Fuino, L., Bali, P., Wittmann, S., Donapaty, S., Guo, F., Yamaguchi, H., Wang, H., Atadja, P. W., & Bhalla, K. N. (2003) · PubMed · Cited by 296
Rosato, R. R., Almenara, J. A., Dai, Y., & Grant, S. (2003) · PubMed · Cited by 267
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Peart, M. J., Tainton, K. M., Ruefli, A. A., Dear, A. E., Sedelies, K. A., O’Reilly, L. A., Waterhouse, N. J., Trapani, J. A., & Johnstone, R. W. (2003) · PubMed · Cited by 233
Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R. A., & Marks, P. A. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.3.1003 · Cited by 220
Self-citationHistone acetyltransferases and deacetylases in the control of cell proliferation and differentiation
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)86002-x · Cited by 205
Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., & Brosch, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049002a · Cited by 184
Xu, W., Ngo, L., Perez, G., Dokmanovic, M., & Marks, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607518103 · Cited by 179
Self-citationInduction of transformed cells to terminal differentiation and the modulation of gene expression.
Marks, P. A., Sheffery, M., & Rifkind, R. A. (1987) · PubMed · Cited by 160
Self-citationAndreeff, M., Stone, R. M., Michaeli, J., Cw, Y., Tong, W., Sogoloff, H., Ervin, T. J., Kufe, D. W., Rifkind, R. A., & Marks, P. (1992) · Blood · doi:10.1182/blood.v80.10.2604.2604 · Cited by 124
Self-citationMitochondria: A novel target for the chemoprevention of cancer
Hail, N. (2005) · APOPTOSIS · doi:10.1007/s10495-005-0792-8 · Cited by 120
Inhibitors of apoptosis proteins in prostate cancer cell lines
McEleny, K. R., Watson, R. W. G., Coffey, R. N. T., O’Neill, A., & Fitzpatrick, J. M. (2002) · The Prostate · doi:10.1002/pros.10061 · Cited by 117
Haggerty, T. J., Zeller, K. I., Osthus, R. C., Wonsey, D. R., & Dang, C. V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931346100 · Cited by 108
Mai, A., Massa, S., Ragno, R., Cerbara, I., Jesacher, F., Loidl, P., & Brosch, G. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021070e · Cited by 106
Yamanaka, K., Rocchi, P., Miyake, H., Fazli, L., Vessella, B., Zangemeister‐Wittke, U., & Gleave, M. E. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0064 · Cited by 101
Potent cytodifferentiating agents related to hexamethylenebisacetamide.
Breslow, R., Jursic, B., Yan, Z. F., Friedman, E., Leng, L., Ngo, L., Rifkind, R. A., & Marks, P. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5542 · Cited by 63
Self-citationMai, A., Massa, S., Pezzi, R., Rotili, D., Loidl, P., & Brosch, G. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034167p · Cited by 60
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S. R. S., Wang, J. G., Frankel, S., Lis, J., & Duvic, M. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7500 · Cited by 42
Li, X., Wong, C., Mysel, R., Slobodov, G., Metwalli, A. R., Kruska, J. D., Manatt, C. S., Culkin, D. J., Kropp, B. P., & Lin, H. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-30 · Cited by 6
Cited by
The molecular hallmarks of epigenetic control
Allis, C. D., & Jenuwein, T. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.59 · Cited by 2,809
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Poynton, F. E., Bright, S. A., Blasco, S., Williams, D. C., Kelly, J. M., & Gunnlaugsson, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00680b · Cited by 421
Metadata
- Authors
- Marks, P. A.
- Venue
- Oncogene
- Published
- 2007-02-26
- Volume
- 26
- Issue
- 9
- Pages
- 1351-1356
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2086384126
- Cited by
- 626
- References
- 49
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.